• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Erasca Inc.

    5/28/24 4:34:40 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ERAS alert in real time by email
    SC 13G 1 d11056386_13-g.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No.)*

     

     

     

    Erasca, Inc.
    (Name of Issuer)

     

     

     

    Common Stock, $0.0001 par value per share
    (Title of Class of Securities)

     

     

     

    29479A108
    (CUSIP Number)

     

     

     

    May 17, 2024
    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [_] Rule 13d-1(b)

     

    [X] Rule 13d-1(c)

     

    [_] Rule 13d-1(d)

     

    __________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     
     
    CUSIP No. 29479A108    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Suvretta Capital Management, LLC  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [_]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      13,768,039  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      13,768,039  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      13,768,039  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)      [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      5.5%  
         
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
         
      IA, OO  
     
     

     

    CUSIP No. 29479A108  

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Averill Master Fund, Ltd.  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
         
        (a)  [_]
        (b)  [_]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Cayman Islands  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      13,768,039  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      13,768,039  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      13,768,039  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)      [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      5.5%  
         
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
         
      CO  

     

     
     

    CUSIP No. 29479A108    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Aaron Cowen  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [_]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      U.S.A.  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      13,768,039  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      13,768,039  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      13,768,039  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)      [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      5.5%  
         
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
         
      IN, HC  

     
     

    CUSIP No. 29479A108  

     

       
    Item 1. (a). Name of Issuer:
         
        Erasca, Inc.
         
      (b). Address of Issuer's Principal Executive Offices:
         
       

    3115 Merryfield Row, Suite 300

    San Diego, CA 92121

     

    Item 2.    
      (a) – (c) Name, Principal Business Address, and Citizenship of Persons Filing:
         
       

    Suvretta Capital Management, LLC – Delaware

    Averill Master Fund, Ltd. – Cayman Islands

        Aaron Cowen – U.S.A.
         
       

    Suvretta Capital Management, LLC:

    540 Madison Avenue, 7th Floor

    New York, New York 10022

       

    United States of America

     

    Averill Master Fund, Ltd.:

    c/o Maples Corporate Services Limited

    P.O. Box 309

    Ugland House

    Grand Cayman KY1-1104

    Cayman Islands

     

    Aaron Cowen:

    c/o Suvretta Capital Management, LLC

    540 Madison Avenue, 7th Floor

    New York, New York 10022

         
      (d).   Title of Class of Securities:
         
        Common Stock, $0.0001 par value per share (the “Common Stock”)
         
      (e). CUSIP Number:
         
        29479A108
         

     

    Item 3.   If This Statement is filed pursuant to ss.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a
         

     

      (a) [_] Broker or dealer registered under Section 15 of the Exchange Act (15 U.S.C. 78c).
           
      (b) [_] Bank as defined in Section 3(a)(6) of the Exchange Act (15 U.S.C. 78c).
           
      (c) [_] Insurance company as defined in Section 3(a)(19) of the Exchange Act (15 U.S.C. 78c).
           
      (d) [_] Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) [_] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
           
      (f) [_] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
           
      (g) [_] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
           
      (h) [_] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);
           
      (i) [_] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j)   [_] Group, in accordance with s.240.13d-1(b)(1)(ii)(J).

     

     
     

    Item 4. Ownership.
     
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a)   Amount beneficially owned:
         
        Suvretta Capital Management, LLC – 13,768,039
        Averill Master Fund, Ltd. – 13,768,039
        Aaron Cowen – 13,768,039
         
      (b)   Percent of class:
         
        Suvretta Capital Management, LLC – 5.5%
        Averill Master Fund, Ltd. – 5.5%
        Aaron Cowen – 5.5%

     

     
      (c)   Number of shares as to which the person has:
         
        (i) Sole power to vote or to direct the vote  
             
          Suvretta Capital Management, LLC – 0
          Averill Master Fund, Ltd. – 0
          Aaron Cowen – 0
             
        (ii)   Shared power to vote or to direct the vote  
             
          Suvretta Capital Management, LLC – 13,768,039
          Averill Master Fund, Ltd. – 13,768,039
          Aaron Cowen – 13,768,039
             
        (iii) Sole power to dispose or to direct the disposition of  
             
          Suvretta Capital Management, LLC – 0
          Averill Master Fund, Ltd. – 0
          Aaron Cowen – 0
             
        (iv)   Shared power to dispose or to direct the disposition of  
             
          Suvretta Capital Management, LLC – 13,768,039
          Averill Master Fund, Ltd. – 13,768,039
          Aaron Cowen – 13,768,039

     

     
    Item 5. Ownership of Five Percent or Less of a Class.
     
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [_].
     
      N/A
       

     
     

     

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified.  A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
     
      N/A  
       
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary.  If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
     
      See Exhibit B attached hereto.
       
       
    Item 8. Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group.  If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.
     
      N/A
       
       
    Item 9. Notice of Dissolution of Group.
     
    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity.  See Item 5.
     
      N/A
       
       
    Item 10. Certification.
     
      (b) The following certification shall be included if the statement is filed pursuant to §240.13d-1(c):
         
        By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
     
     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      May 28, 2024
      (Date)
       
      Suvretta Capital Management, LLC*
       
      By:  /s/ Aaron Cowen
      (Signature)
       
      Authorized Signatory
     

    (Name/Title)

     

    Averill Master Fund, Ltd.*

       
      By:  /s/ Aaron Cowen
      (Signature)
       
      Director
      (Name/Title)
     

     

    Aaron Cowen*

     

      /s/ Aaron Cowen
      (Signature)
       
       

    *Each Reporting Person disclaims beneficial ownership over the securities reported herein except to the extent of its pecuniary interest therein.

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     

     

     
     

     

    Exhibit A

     

    AGREEMENT

     

    The undersigned agree that this Schedule 13G dated May 28, 2024 relating to the Common Stock of Erasca, Inc. shall be filed on behalf of the undersigned.

      May 28, 2024
      (Date)
       
      Suvretta Capital Management, LLC
       
      By:  /s/ Aaron Cowen
      (Signature)
       
      Authorized Signatory
     

    (Name/Title)

     

    Averill Master Fund, Ltd.

       
      By:  /s/ Aaron Cowen
      (Signature)
       
      Director
      (Name/Title)
     

     

    Aaron Cowen

     

      /s/ Aaron Cowen
      (Signature)
       
       

     

     
     

     

    Exhibit B

     

    Aaron Cowen has beneficial ownership by virtue of his role as a control person of Suvretta Capital Management, LLC.

     

     

     

     

     

     

     

     

     

     

     

     

     

    Get the next $ERAS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ERAS

    DatePrice TargetRatingAnalyst
    8/18/2025$2.00Overweight → Equal-Weight
    Morgan Stanley
    3/26/2025$5.00Outperform
    Raymond James
    11/18/2024$6.00Buy
    Jefferies
    3/11/2024$8.00Overweight
    CapitalOne
    1/5/2024$11.00 → $6.00Buy → Neutral
    BofA Securities
    10/11/2023$10.00Buy
    H.C. Wainwright
    3/30/2023$9.00Buy
    Mizuho
    2/24/2023$10.00Buy
    Goldman
    More analyst ratings

    $ERAS
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Erasca Inc.

    SCHEDULE 13G - Erasca, Inc. (0001761918) (Subject)

    8/13/25 8:14:21 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3 filed by Erasca Inc.

    S-3 - Erasca, Inc. (0001761918) (Filer)

    8/12/25 4:45:10 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Erasca Inc.

    10-Q - Erasca, Inc. (0001761918) (Filer)

    8/12/25 4:27:06 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ERAS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Erasca downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Erasca from Overweight to Equal-Weight and set a new price target of $2.00

    8/18/25 8:49:16 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Raymond James initiated coverage on Erasca with a new price target

    Raymond James initiated coverage of Erasca with a rating of Outperform and set a new price target of $5.00

    3/26/25 7:49:37 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies initiated coverage on Erasca with a new price target

    Jefferies initiated coverage of Erasca with a rating of Buy and set a new price target of $6.00

    11/18/24 7:43:18 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ERAS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Erasca Reports Second Quarter 2025 Business Updates and Financial Results

    Efficient execution accelerated clinical entry of pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 Phase 1 monotherapy data for RAS-targeting franchise expected in 2026 Robust balance sheet with cash, cash equivalents, and marketable securities of $387 million as of June 30, 2025 is expected to fund operations into H2 2028 SAN DIEGO, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today provided business updates and reported financial results for the fiscal quarter ended June 30, 2025.

    8/12/25 4:01:00 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oncology Innovation Just Hit a Turning Point -- Here's What to Watch

    USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- USA News Group News Commentary – The oncology landscape is being pulled in two directions. On one hand, U.S. cancer death rates continue to decline. On the other, global cases are expected to rise sharply—while early-onset diagnoses in younger patients are climbing at a troubling pace. At the same time, proposed federal budget cuts threaten to slash funding for the National Cancer Institute by up to 40%, raising concerns about the future of publicly funded research. With public resources under pressure, much of the innovation burden is shifting to the private sector, where a

    6/30/25 11:02:00 AM ET
    $ARAY
    $CLRB
    $ERAS
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    Erasca Announces IND Clearance for Potential First-in-Class and Best-in-Class Pan-KRAS Inhibitor ERAS-4001

    Both ERAS-4001 and potential best-in-class pan-RAS molecular glue ERAS-0015 received IND clearance in May ahead of company guidance Initial Phase 1 monotherapy data for both RAS-targeting programs expected in 2026 SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced clearance of an investigational new drug (IND) application by the United States Food and Drug Administration (FDA) for ERAS-4001, a potential first-in-class and best-in-class pan-KRAS inhibitor, for the treatment of patie

    6/2/25 8:00:00 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ERAS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Varney Michael David

    4 - Erasca, Inc. (0001761918) (Issuer)

    6/26/25 4:28:03 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Liu Jean I

    4 - Erasca, Inc. (0001761918) (Issuer)

    6/26/25 4:27:26 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Hambleton Julie

    4 - Erasca, Inc. (0001761918) (Issuer)

    6/26/25 4:27:06 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ERAS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Casdin Alexander W. bought $181,920 worth of shares (80,000 units at $2.27) (SEC Form 4)

    4 - Erasca, Inc. (0001761918) (Issuer)

    5/22/24 6:57:45 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Start Valerie Denise Harding bought $18,480 worth of shares (10,000 units at $1.85) (SEC Form 4)

    4 - Erasca, Inc. (0001761918) (Issuer)

    12/8/23 9:10:12 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lim Jonathan E bought $1,696,179 worth of shares (1,000,000 units at $1.70) (SEC Form 4)

    4 - Erasca, Inc. (0001761918) (Issuer)

    12/6/23 7:41:47 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ERAS
    Leadership Updates

    Live Leadership Updates

    View All

    Oncology Innovation Just Hit a Turning Point -- Here's What to Watch

    USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- USA News Group News Commentary – The oncology landscape is being pulled in two directions. On one hand, U.S. cancer death rates continue to decline. On the other, global cases are expected to rise sharply—while early-onset diagnoses in younger patients are climbing at a troubling pace. At the same time, proposed federal budget cuts threaten to slash funding for the National Cancer Institute by up to 40%, raising concerns about the future of publicly funded research. With public resources under pressure, much of the innovation burden is shifting to the private sector, where a

    6/30/25 11:02:00 AM ET
    $ARAY
    $CLRB
    $ERAS
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    Erasca Appoints Jean Liu to its Board of Directors

    SAN DIEGO, April 27, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the appointment of Jean Liu to its board of directors and to its audit committee. Ms. Liu brings over 20 years of professional experience advising biopharmaceutical companies on corporate, intellectual property, compliance, and general legal matters. "Jean Liu has been a seasoned executive with Seagen during its transformation into a leading global, multiproduct oncology company, and she also is one of the most strategic busine

    4/27/22 8:00:00 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Erasca Strengthens Leadership Team with Two Key Executive Appointments

    Lisa Tesvich-Bonora appointed as Chief People Officer Robert Shoemaker promoted to Senior Vice President of Research SAN DIEGO, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the appointment of Lisa Tesvich-Bonora as Chief People Officer and the promotion of Robert Shoemaker to Senior Vice President of Research. "I am thrilled to welcome Lisa to the Erasca family. With over two decades of experience in creating collaborative and engaging environments where employees can thrive, she bring

    1/18/22 8:00:00 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ERAS
    Financials

    Live finance-specific insights

    View All

    Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise

    Pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 are potent, oral inhibitors with potential best-in-class profiles in RASm solid tumors Pipeline prioritization and workforce restructuring sharpens focus on programs targeting the highest unmet needs and with highest probability of success Priced concurrent $160 million equity offering Erasca to host conference call and webcast Friday, May 17, 2024 at 8:30 am ET SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today anno

    5/16/24 8:02:00 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Erasca Reports First Quarter 2024 Business Updates and Financial Results

    Median OS of 13-14 months for naporafenib plus trametinib in pooled analysis of patients with NRASm melanoma Strengthened balance sheet with private placement financing from high-quality new and existing healthcare-focused investors Pro forma cash, cash equivalents, and marketable securities of $334 million is expected to fund operations into H2 2026 SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today provided business updates and reported financial results for the fiscal quarter ended March

    5/8/24 4:01:00 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results

    Gained global registrational clarity for naporafenib and achieved key clinical milestones for naporafenib, ERAS-007, and ERAS-801 Multiple data readouts expected in 2024 for naporafenib (SEACRAFT-1), ERAS-007 (HERKULES-3), and ERAS-801 (THUNDERBBOLT-1) and planned initiation of pivotal SEACRAFT-2 trial Robust balance sheet with cash, cash equivalents, and marketable securities of $322 million as of December 31, 2023 Erasca to host R&D update conference call and webcast Thursday, March 28, 2024 at 8:30 am ET SAN DIEGO, March 27, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and comm

    3/27/24 4:01:00 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ERAS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Erasca Inc.

    SC 13G/A - Erasca, Inc. (0001761918) (Subject)

    11/14/24 5:13:04 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Erasca Inc.

    SC 13G/A - Erasca, Inc. (0001761918) (Subject)

    11/14/24 4:04:32 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Erasca Inc.

    SC 13G - Erasca, Inc. (0001761918) (Subject)

    11/14/24 1:28:34 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care